Amyloid Beta Peptide 1-42 (HFIP treated) Monomers
Produktgrößen
100 ug
£214,00
SPR-485-100UG
5 x 100 ug
£434,00
SPR-485-5X100UG
Über dieses Produkt
- SKU:
- SPR-485
- Zusätzliche Namen:
- AB Beta 1-42, Amyloid beta, Beta amyloid peptide, Abeta, Abeta peptide, Amyloid beta precursor peptide, APP, Beta-APP42, Abeta42, A4, ABPP, APPI, Alzheimer disease amyloid A4, Alzheimer disease amyloid, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, PN-II
- Anwendung:
- Cell-based/Functional Assay, Western Blot
- Buffer:
- Dry powder. See "Other Resources" for re-suspension instructions/protocol.
- CE/IVD:
- RUO
- Weitere Details:
- Amyloid beta (AB Beta) peptides, derived from the proteolytic cleavage of the amyloid precursor protein (APP), are central to the pathology of Alzheimer's disease. Among these, the 42-residue variant (AB Beta 1-42) is particularly aggregation-prone and neurotoxic. In its monomeric form, AB Beta 1-42 plays a critical role in the early stages of disease progression, serving as the molecular seed for oligomer and fibril formation. AB Beta 1-42 monomers exhibit distinct biochemical properties, including a higher hydrophobicity and B Beta-sheet propensity compared to shorter isoforms like AB Beta 1-40. These features make AB Beta 1-42 more likely to misfold and self-assemble into soluble oligomers and insoluble fibrils, which accumulate as amyloid plaques in the brain. Even before aggregation, monomeric AB Beta can disrupt synaptic function, induce oxidative stress, and trigger inflammatory responses. In neurodegenerative disease research, AB Beta 1-42 monomers are essential for modeling the initiation of amyloidogenesis. Their use in in vitro and in vivo systems enables detailed investigation of misfolding kinetics, membrane interactions, and neurotoxicity. These monomers also serve as a baseline for evaluating therapeutic strategies aimed at stabilizing native AB Beta, preventing aggregation, and mitigating early neuronal damage. By capturing the earliest molecular events in Alzheimer's pathology, AB Beta 1-42 monomers provide a foundational platform for advancing biomarker discovery and the development of disease-modifying treatments. StressMarq's amyloid beta peptide 1-42 (AB Beta42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in Ammonium hydroxide (NH4OH), StressMarq's AB Beta42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, AB Beta42 monomers are not toxic to primary rat cortical neurons.
- Immunogen:
- Amyloid Beta Monomers
- Molekulargewicht:
- 4.5 kDa
- Reinheit:
- >98%
- Sequenz:
- DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- -70[o]C
- Hersteller:
- StressMarq Biosciences
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Synthetic
- Datenblatt des Herstellers:https://www.stressmarq.com/products/protein/amyloid-beta-protein-spr-485/